课题基金 / 基金详情

LCCC 0310 DENDRITIC CELL VACCINE GIVEN WITH TRASTUZUMAB AND VINORELBINE

LCCC 0310 DENDRITIC CELL VACCINE GIVEN WITH TRASTUZUMAB AND VINORELBINE
LCCC 0310 树突状细胞疫苗，含曲妥珠单抗和长春瑞滨
批准号：
7625547
负责人：
Jonathan S. Serody
金额：
$0.53万
依托单位：
UNIV OF NORTH CAROLINA CHAPEL HILL
依托单位国家：
美国
项目类别：
财政年份：
2006
资助国家：
美国
项目状态：
已结题
起止时间：
2006-12-01 至 2007-11-30
来源：
https://reporter.nih.gov/project-details/7625547
关键词：
AntibodiesComputer Retrieval of Information on Scientific Projects DatabaseDendritic Cell VaccineDendritic CellsFundingGrantInstitutionPurposeResearchResearch PersonnelResourcesSourceTestingTrastuzumabTrastuzumab/VinorelbineUnited States National Institutes of HealthVinorelbinechemotherapykillingsneoplastic cell

项目摘要

项目成果

Jonathan S. Serody的其他基金

相关文献

中文摘要
翻译
这个子项目是许多研究子项目中利用 资源由NIH/NCRR资助的中心拨款提供。子项目和 调查员(PI)可能从NIH的另一个来源获得了主要资金， 并因此可以在其他清晰的条目中表示。列出的机构是 该中心不一定是调查人员的机构。 这项研究的目的是测试给予树突状细胞化疗(称为长春瑞滨)和一种抗体(称为曲妥珠单抗)是否会比之前发现的不使用树突状细胞而给予化疗和抗体的情况更有效。
英文摘要
This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The purpose of this study is to test whether giving dendritic cells with chemotherapy (called vinorelbine) and an antibody (called trastuzumab), which are effective in killing tumor cells, will be more effective than what has been previously found with giving the chemotherapy and antibody without using dendritic cells.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
UNC Immunotherapy Training Grant (IM-TAG)
SToP Cancer SPORE: Career Enhancement Program
SToP Cancer SPORE: Career Enhancement Program
Enhancing Innate Immune Reconstitution Post Allogeneic HSCT.